These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 23462722)

  • 1. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients.
    Huillard O; Mir O; Peyromaure M; Tlemsani C; Giroux J; Boudou-Rouquette P; Ropert S; Delongchamps NB; Zerbib M; Goldwasser F
    Br J Cancer; 2013 Mar; 108(5):1034-41. PubMed ID: 23462722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Body Composition by Computed Tomography as a Predictor of Toxicity in Patients With Renal Cell Carcinoma Treated With Sunitinib.
    Cushen SJ; Power DG; Teo MY; MacEneaney P; Maher MM; McDermott R; O'Sullivan K; Ryan AM
    Am J Clin Oncol; 2017 Feb; 40(1):47-52. PubMed ID: 24685884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.
    Bourlon MT; Gao D; Trigero S; Clemons JE; Breaker K; Lam ET; Flaig TW
    Cancer Med; 2016 Dec; 5(12):3386-3393. PubMed ID: 27758076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma.
    Iwamoto K; Ishihara H; Takagi T; Kondo T; Yoshida K; Iizuka J; Tanabe K
    Med Oncol; 2018 Apr; 35(6):78. PubMed ID: 29687160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
    Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
    Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.
    Kim HR; Park HS; Kwon WS; Lee JH; Tanigawara Y; Lim SM; Kim HS; Shin SJ; Ahn JB; Rha SY
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):825-35. PubMed ID: 24013576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma.
    Antoun S; Baracos VE; Birdsell L; Escudier B; Sawyer MB
    Ann Oncol; 2010 Aug; 21(8):1594-1598. PubMed ID: 20089558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
    Najjar YG; Mittal K; Elson P; Wood L; Garcia JA; Dreicer R; Rini BI
    Eur J Cancer; 2014 Apr; 50(6):1084-9. PubMed ID: 24559686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma.
    Rini BI; Stein M; Shannon P; Eddy S; Tyler A; Stephenson JJ; Catlett L; Huang B; Healey D; Gordon M
    Cancer; 2011 Feb; 117(4):758-67. PubMed ID: 20922784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kusuda Y; Harada K; Sakai I; Fujisawa M
    Int J Clin Oncol; 2013 Feb; 18(1):81-6. PubMed ID: 22095244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.
    Powles T; Sarwar N; Jones R; Wilson P; Boleti E; Protheroe A; Crabb SJ; Shamash J; Stockdale A; Rashid S; Nathan P; Chowdury S
    Eur J Cancer; 2012 Nov; 48(17):3171-6. PubMed ID: 22766517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.
    Castellano D; Maroto JP; Espinosa E; Grande E; Bolós MV; Llinares J; Esteban E; González Del Alba A; Climent MA; Arranz JA; Méndez MJ; Fernández Parra E; Antón-Aparicio L; Bayona C; Gallegos I; Gallardo E; Samaniego L; García Donas J
    Expert Opin Drug Saf; 2018 Jun; 17(6):573-579. PubMed ID: 28535693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
    Josephs D; Hutson TE; Cowey CL; Pickering LM; Larkin JM; Gore ME; Van Hemelrijck M; McDermott DF; Powles T; Chowdhury P; Karapetis C; Harper PG; Choueiri TK; Chowdhury S
    BJU Int; 2011 Oct; 108(8):1279-83. PubMed ID: 21244613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
    Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D
    Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
    Shi HZ; Tian J; Chen X; Wang D; Li CL
    Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.
    Patel KB; Panchal HP; Karanwal AB; Parekh BB; Shah S; Prasad S
    Indian J Cancer; 2016; 53(1):118-22. PubMed ID: 27146758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
    Kim JH; Park I; Lee JL
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).
    Grünwald V; Desar IM; Haanen J; Fiedler W; Mouritzen U; Olsen MW; van Herpen CM
    Acta Oncol; 2011 Jan; 50(1):121-6. PubMed ID: 21174612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
    Rini BI; Cohen DP; Lu DR; Chen I; Hariharan S; Gore ME; Figlin RA; Baum MS; Motzer RJ
    J Natl Cancer Inst; 2011 May; 103(9):763-73. PubMed ID: 21527770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.